Enhanced Immunoassay Diagnostic System Launched

Publication
Article
OncologyONCOLOGY Vol 16 No 5
Volume 16
Issue 5

Abbott Laboratories recently announced the launch of AxSYM Plus, an enhanced version of its AxSYM automated immunoassay instrument system.

Abbott Laboratories recently announcedthe launch of AxSYM Plus, an enhanced version of its AxSYM automated immunoassayinstrument system. Among the new features included in the system are advancedcomputer software for automatic troubleshooting, improved ergonomics, and apressure monitoring system for determining the integrity of patient samples.

Instrument’s Capabilities

"AxSYM Plus represents our commitment to continue investingin this exceptional technology, which has had a significant impact on ourcustomers and their ability to more efficiently manage their laboratoryoperations," said Thomas D. Brown, senior vice president, diagnosticoperations, Abbott Laboratories.

The system combines a broad menu of tests with continuousaccess, random access, and stat testing capabilities. Key features of theinstrument include a menu of more than 75 assays for various diseases andmedical conditions including hepatitis, the human immunodeficiency virus (HIV),cancer, thyroid conditions, anemia, and pregnancy; full disease state panels;and multiple technologies (including microparticle enzyme immunoassay andfluorescence polarization immunoassay) for optimal test results.

In addition, AxSYM Plus offers continuous and random accesstesting capability for maximum operating efficiency with various workloads inthe laboratory, stat testing capability with results available in as little as11 minutes, throughput of up to 120 tests per hour, positive identification ofbar code samples, touch-screen computer monitor, and the ability to trackinventory and waste levels automatically.

Recent Videos
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
9 Experts are featured in this series.
9 Experts are featured in this series.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
2 experts are featured in this series.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
9 Experts are featured in this series.
Related Content